Clinical trial
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00196716 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00196716 |
|---|---|
| Title | A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease |
| Official title | A Multicenter, Open-label Study of Low Dose Maintenance Treatment of Fabrazyme (Recombinant Human Alpha-Galactosidase A (R-h Alpha-GAL)) Replacement Therapy in Patients With Fabry Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Biological |
| Interventions | Fabrazyme (agalsidase beta) |
| Enrollment | 21 |
| Start date | Jun 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 3, 2015 |
| Countries | Czechia, Estonia, Poland, Slovakia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: